Section Arrow
Quote
CUVL.NASDAQ
- Clinuvel Pharmaceuticals Limited
Quotes are at least 15-min delayed:2026/08/02 00:36 EDT
Regular Hours
Last
 6.49
-0.44 (-6.35%)
Day High 
7.1127 
Prev. Close
6.93 
1-M High
8.19 
Volume 
4.11K 
Bid
2.68
Ask
7.26
Day Low
6.49 
Open
6.55 
1-M Low
6.21 
Market Cap 
349.47M 
Currency 美元 
P/E -- 
%Yield 0.51 
10-SMA 7.08 
20-SMA 7.15 
50-SMA 6.9 
52-W High 9 
52-W Low 5.98 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.64/0.83
Enterprise Value
349.47M
Balance Sheet
Book Value Per Share
3.45
Cash Flow
Cash Flow Yield
0.08
Income Statement
Total Revenue
95.02M
Operating Revenue Per Share
1.03
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
REPLReplimune Group11.2+5.79+107.02%-- 
GOSSGossamer Bio0.1695-0.0088-4.94%-- 
JUNSJupiter Neurosciences Inc0.09-0.0075-7.69%-- 
KPTIKaryopharm Therapeutics Inc.1.92-5.09-72.61%-- 
IOVAIovance Biotherapeutics4.07-0.62-13.22%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.